Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Ainuovirine + lamivudine + tenofovir for dyslipidemia or weight gain in treatment-experienced adults with HIV-1
ChiCTR2400082609Phase 4Not yet recruiting
- Sponsor
- The Sixth People's Hospital of Zhengzhou
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ainuovirine, lamivudine and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1, sponsored by The Sixth People's Hospital of Zhengzhou. Primary endpoints: HIV RNA <50 copies/mL and Lipid profile. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
ainuovirinelamivudinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR2400082609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082609.